Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 6, 2012, Pages 471-476

  Compare, D ^a   Coccoli, P ^a   Rocco, A ^a   Nardone, O M ^a   De Maria, S ^a   Carteni M ^a   Nardone, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bacterial translocation; Endotoxemia; Gut microbiota; Non alcoholic fatty liver disease; Probiotics

Indexed keywords

ANIMAL; BACTERIAL TRANSLOCATION; DISEASE MODEL; FATTY LIVER; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMAN; LIVER; METABOLIC DISORDER; METAGENOME; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BACTERIAL TRANSLOCATION; DISEASE MODELS, ANIMAL; FATTY LIVER; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMANS; LIVER; METABOLIC DISEASES; METAGENOME;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 84861197530     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.02.007     Document Type: Review

References (50)

1. Son G., Kremer M., Hines I.N. Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract 2010, Epub 2010 Jul 28.
2. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet 2003, 361(9356):512-519.
3. Abt M.C., Artis D. The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis. Curr Opin Gastroenterol 2009, 25(6):496-502.
4. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 2005, 308(5728):1635-1638.
5. O'Hara A.M., Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006, 7(7):688-693.
6. Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136(1):65-80.
7. Zhang G., Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001, 107(1):13-19.
8. Clavel T., Haller D. Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation. Curr Issues Intest Microbiol 2007, 8(2):25-43.
9. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002, 16(6):915-931.
10. Xu J., Gordon J.I. Honor thy symbionts. Proc Natl Acad Sci U S A 2003, 100(18):10452-10459.
11. Wells J.M., Rossi O., Meijerink M., van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 2011, 108(Suppl. 1):4607-4614.
12. Cani P.D., Delzenne N.M. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009, 15(13):1546-1558.
13. Othman M., Agüero R., Lin H.C. Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol 2008, 24(1):11-16.
14. Nagata K., Suzuki H., Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007, 32(5):453-468.
15. Zeuzem S. Gut-liver axis. Int J Colorectal Dis 2000, 15(2):59-82.
16. Han D.W. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol 2002, 8(6):961-965.
17. Bilzer M., Roggel F., Gerbes A.L. Role of Kupffer cells in host defense and liver disease. Liver Int 2006, 26(10):1175-1186.
18. Jirillo E., Caccavo D., Magrone T., Piccigallo E., Amati L., Lembo A., et al. The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 2002, 8(5):319-327.
19. Bedogni G., Gastaldelli A., Manco M., De Col A., Agosti F., Tiribelli C., et al. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis 2010 Sep 27, [Epub ahead of print] PubMed PMID: 20880682.
20. Succurro E., Arturi F., Grembiale A., Iorio F., Fiorentino T.V., Andreozzi F., et al. One-hour post-load plasma glucose levels are associated with elevated liver enzymes. Nutr Metab Cardiovasc Dis 2011, 21(9):713-718.
21. Abete I., Goyenechea E., Zulet M.A., Martínez J.A. Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis 2011, 21(Suppl. 2):B1-15.
22. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
23. Law K., Brunt E.M. Nonalcoholic fatty liver disease. Clin Liver Dis 2010, 14(4):591-604.
24. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846.
25. Vanni E., Bugianesi E. The gut-liver axis in nonalcoholic fatty liver disease: another pathway to insulin resistance?. Hepatology 2009, 49(6):1790-1792.
26. Solga S.F., Diehl A.M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003, 38:681-687.
27. Diamant M., Blaak E.E., de Vos W.M. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?. Obes Rev 2011, 12(4):272-281.
28. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Königsrainer A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138(8):1452-1455.
29. Miele L., Valenza V., La Torre G., Montalto M., Cammarota G., Ricci R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49(6):1877-1887.
30. Pappo I., Bercovier E.M., Berry Y., Haviv R., Gallily H.R., Freund H. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat. J Surg Res 1991, 51:106-112.
31. Drenick E.J., Fisler J., Johnson D. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82:535-548.
32. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7(12):691-701.
33. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444(7122):1027-1031.
34. Bäckhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101(44):15718-15723.
35. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006 Dec 21, 444(7122):1022-1023.
36. Spencer M.D., Hamp T.J., Reid R.W., Fischer L.M., Zeisel S.H., Fodor A.A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140(3):976-986.
37. Szabo G., Velayudham A., Romics L., Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005, 29(11 Suppl.):140S-145S.
38. Miura K., Seki E., Ohnishi H., Brenner D.A. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847.
39. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007, 47(4):571-579.
40. Rivera C.A., Gaskin L., Allman M., Pang J., Brady K., Adegboyega P., et al. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol 2010, 10:52.
41. Miura K., Kodama Y., Inokuchi S., Schnabl B., Aoyama T., Ohnishi H., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139(1):323-334.
42. Minocha A. Probiotics for preventive health. Nutr Clin Pract 2009, 24:227-241.
43. Nardone G., Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol 2004, 38(Suppl. 6):S121-S122.
44. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37(2):343-350.
45. Ewaschuk J., Endersby R., Thiel D., Diaz H., Backer J., Ma M., et al. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 2007, 46(3):841-850.
46. Ma X., Hua J., Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008, 49(5):821-830.
47. Velayudham A., Dolganiuc A., Ellis M., Petrasek J., Kodys K., Mandrekar P., et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009, 49(3):989-997.
48. Nardone G., Compare D., Liguori E., Di Mauro V., Rocco A., Barone M., et al. Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol 2010, 299(3):G669-G676.
49. Aller R., De Luis D.A., Izaola O., Conde R., Gonzalez Sagrado M., Primo D., et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011, 15(9):1090-1095.
50. Parnell J.A., Raman M., Rioux K.P., Reimer R.A. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int 2011 Dec 30, 10.1111/j.1478-3231.2011.02730.x.